Value Based Payment for Gene Therapy

In The News,

Sep 19 2022

Value Based Payment for Gene Therapy

ADVI helped develop an outcomes-based payment approach for a one-time, curative gene therapy manufacturer to use in reimbursement discussions with state Medicaid programs and commercial payers. ADVI’s gene therapy experience spans 16 different manufacturers and 20 different therapeutic areas.